 Clinical Oncology News | Hematology & Stem Cell Transplantation Program Clinical Oncology News The majority of clinical responses with SAR3419 were seen in patients with follicular lymphoma, including those who were rituximab refractory. SAR3419 (huB4-DM4) is a humanized immunoglobulin G1 anti-CD19 monoclonal antibody. A second Phase I/II ... |
